Despite Warnings, Co-Medication with Proton Pump Inhibitors and Dasatinib is Common in Chronic Myeloid Leukemia, but XS004, a Novel Oral Dasatinib Formulation, Provides Reduced Ph-Dependence, Minimizing Undesirable Drug-Drug Interactions.